Albion News

Bravo Inns
Bravo was founded in May 2007 by Ken Buckley and Philip Dearden, together with financial support from Albion Capital.  In early 2007, Ken, Phil and Albion successfully exited The Bold Pub Company, an estate of 30 pubs. The Bravo estate currently comprises 44 predominantly freehold and well-invested pubs trading under the successful operator managed model.  Profits have increased from £1.9m in 2017 to in excess of £2.6m today due to selective site acquisitions and growth capital investment. Following completion of the sale, Ken Buckley will continue as a consultant to the business and the... read more
Fishmongers' Hall.jpg
Many thanks to all those that joined us at The Fishmongers' Hall for another very successful seminar Some of the slides from this event are available on request. Please contact read more
Congratulations to Mike Parsons, Chairman of Albion Care Communities, who won the 'Non Executive Director 2019' at the HealthInvestor Power Fifty Awards 2019.  The HealthInvestor Power Fifty NED prize is given to an individual who has shown themselves to be a dynamic, must-have non-executive director or chairman of a health and social care company by being the perfect foil to the executive teams and an invaluable font of knowledge. Mike founded Barchester Healthcare and was its Group CEO between 1992 and 2013. During this period Barchester grew rapidly, both organically and through... read more
Lancashire-based ELE provides highly specialised technology, including advanced robotics, to precision engineer components for the aerospace, power and automotive sectors for clients including GE, Rolls-Royce and Siemens. In its latest financial year, ELE generated revenues of almost £14 million, and currently employs more than 180 people from its facilities in Colne, Lancashire, and Trencin, Slovakia. Robert Whitby-Smith, Partner, Albion, says: “As a long-term supporter of ELE, we are delighted to have achieved a total return of 4x cost for our investors and that ELE has found a strong... read more
We are delighted to announce that Siemens AG has announced plans to acquire Process Systems Enterprise (PSE), the leading supplier of Advanced Process Modelling (APM) software and services.  PSE built a category leading industrial software business, and the excellent return is driven by a combination of strong growth (10X software revenue since AlbionVC’s initial investment) with top decile capital efficiency - little more than the £2m invested by AlbionVC raised by the company over its lifetime. The exit represents a return of c.10x for the Albion VCTs. Process Systems Enterprise (PSE), the... read more
Abcodia will establish offices in the Wuxi International Life Science Innovation Campus (“I·Campus”), which has been created by WND and AstraZeneca. I·Campus is an innovation incubation platform offering services in R&D, commercialization and professional services in the life science industry for domestic and foreign companies looking to establish or expand their presence in China. From this location, Abcodia will work collaboratively with AstraZeneca and other partners in a life science innovative ecosystem to establish its ovarian cancer screening technology in China.   China represents... read more
Albion-NewHome.jpg We've recently moved offices! After 10 years in Bank, we've moved to a new office in Farringdon! Our new address is: 1 Benjamin Street, London, EC1M 5QL - our telephone number isn’t changing. read more
Will Fraser-Allen
After more than 23 years as Managing Director, and then Managing Partner of Albion Capital, Patrick Reeve has become Chairman of the business in a newly created role, with Will Fraser-Allen moving to Managing Partner, and Andrew Elder becoming Deputy Managing Partner. From April, Patrick Reeve will chair the Albion and OLIM boards and continue to be involved in directing the strategy of the business, whilst maintaining key relationships across the Albion Capital VCT range, Albion Community Power and the UCL Technology Fund. Patrick joined Close Brothers in 1989, established Close Ventures in... read more
Orchard Therapeutics, a commercial-stage biopharmaceutical company, presented their two-year follow-up data in 20 patients from the registrational trial evaluating OTL-101, aimed at treating those with adenosine deaminase deficiency (ADA-SCID). They achieved a 100% Overall Survival and 100% Event Free Survival in Patients Treated with OTL-101; compared to 88% OS and 56% EvFS with Historical HSCT Overall at 24 months ADA-SCID is a rare, life-threatening, inherited disease caused by mutations in the ADA gene. Patients with ADA-SCID are unable to fight off and frequently succumb to complications... read more
2018 2019 Securities Note
The documents relating to the Offers are now avaible on the Current Offers page read more